Clinical Trial: Tigecycline for Treatment of Rapidly Growing Mycobacteria
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Use of Tigecycline for Treatment of Serious Infection Due to Rapidly Growing Mycobacteria (Especially M.Abscessus)
Brief Summary: To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).
Detailed Summary: To assess the safety and efficacy of tigecycline in the treatment of drug resistant rapidly growing mycobacterial disease especially M. abscessus
Sponsor: The University of Texas Health Science Center at Tyler
Current Primary Outcome: Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be evaluated monthly for one to two years or as deemed necessary ]
Original Primary Outcome: Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be evaluated monthly for one to two years or as deemed necessary ]
Current Secondary Outcome: Microbiological Cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be evaluated monthly for one to two years or as deemed necessary ]
Original Secondary Outcome: Microbiological Cultures [ Time Frame: Monthly while on treatment, then followup after therapy discontinuation will be evaluated monthly for one to two years or as deemed necessary ]
Information By: The University of Texas Health Science Center at Tyler
Dates:
Date Received: January 14, 2008
Date Started: April 2002
Date Completion:
Last Updated: May 18, 2017
Last Verified: May 2017
